National Pension Service Raises Stake in The Cooper Companies, Inc. $COO

National Pension Service grew its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 9,314.0% in the second quarter, Holdings Channel reports. The fund owned 526,149 shares of the medical device company’s stock after purchasing an additional 520,560 shares during the period. National Pension Service’s holdings in Cooper Companies were worth $37,730,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of COO. California State Teachers Retirement System boosted its position in shares of Cooper Companies by 6,101.7% during the 2nd quarter. California State Teachers Retirement System now owns 19,460,014 shares of the medical device company’s stock valued at $1,395,478,000 after acquiring an additional 19,146,230 shares during the last quarter. BlackRock Inc. acquired a new stake in Cooper Companies during the second quarter worth about $1,077,762,000. Generation Investment Management LLP acquired a new stake in Cooper Companies during the second quarter worth about $356,304,000. Wellington Management Group LLP raised its stake in Cooper Companies by 332.9% during the third quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after purchasing an additional 4,756,178 shares during the period. Finally, Jupiter Topco LLC purchased a new position in Cooper Companies during the second quarter worth about $305,074,000. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Trading Down 0.5%

Shares of COO stock opened at $53.91 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.78. The firm has a market cap of $10.25 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a 50-day moving average of $71.62 and a two-hundred day moving average of $69.70. The Cooper Companies, Inc. has a 1-year low of $51.01 and a 1-year high of $89.83.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The business’s revenue was up .5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, analysts predict that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies announced that its Board of Directors has initiated a share repurchase plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the medical device company to buy up to 22.7% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Wall Street Analyst Weigh In

COO has been the topic of several recent analyst reports. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. Robert W. Baird set a $61.00 price target on shares of Cooper Companies and gave the stock a “neutral” rating in a report on Thursday. JPMorgan Chase & Co. decreased their price objective on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating on the stock in a report on Thursday. UBS Group lowered their price objective on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, Mizuho set a $75.00 target price on Cooper Companies and gave the stock an “outperform” rating in a research note on Thursday. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Cooper Companies presently has a consensus rating of “Hold” and an average price target of $71.47.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.